Tech Funding News· Abhinaya Prabhu·· 2 hours agoTop DealsAI Score78
Nouscom raises $135M Series D to test cancer prevention vaccine NOUS-209
Swiss biotech Nouscom secures $135M, pushing cancer prevention vaccine forward
AI Overview
Nouscom raised a $135M Series D co-led by M Ventures and Revelation Partners to fund a global registration-enabling trial of NOUS-209.
Why it matters
The round shows what a registration-enabling prevention trial costs in Europe, and the story is candid that the Phase 1b/2 data had no control group.
Source:Tech Funding News · techfundingnews.com
Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing